134 related articles for article (PubMed ID: 31376782)
1. Arylboronate prodrugs of doxorubicin as promising chemotherapy for pancreatic cancer.
Skarbek C; Serra S; Maslah H; Rascol E; Labruère R
Bioorg Chem; 2019 Oct; 91():103158. PubMed ID: 31376782
[TBL] [Abstract][Full Text] [Related]
2. A glutathione-responsive sulfur dioxide polymer prodrug as a nanocarrier for combating drug-resistance in cancer chemotherapy.
Shen W; Liu W; Yang H; Zhang P; Xiao C; Chen X
Biomaterials; 2018 Sep; 178():706-719. PubMed ID: 29433753
[TBL] [Abstract][Full Text] [Related]
3. Dual-Sensitive Charge-Conversional Polymeric Prodrug for Efficient Codelivery of Demethylcantharidin and Doxorubicin.
Wu Y; Zhou D; Zhang Q; Xie Z; Chen X; Jing X; Huang Y
Biomacromolecules; 2016 Aug; 17(8):2650-61. PubMed ID: 27384255
[TBL] [Abstract][Full Text] [Related]
4. Ultrasound triggered phase-change nanodroplets for doxorubicin prodrug delivery and ultrasound diagnosis: An in vitro study.
Gao J; Yu B; Li C; Xu M; Cao Z; Xie X; Wang W; Liu J
Colloids Surf B Biointerfaces; 2019 Feb; 174():416-425. PubMed ID: 30481702
[TBL] [Abstract][Full Text] [Related]
5. Intracellular Activation of a Prostate Specific Antigen-Cleavable Doxorubicin Prodrug: A Key Feature Toward Prodrug-Nanomedicine Design.
Pereira SGT; Hudoklin S; Kreft ME; Kostevsek N; Stuart MCA; Al-Jamal WT
Mol Pharm; 2019 Apr; 16(4):1573-1585. PubMed ID: 30802065
[TBL] [Abstract][Full Text] [Related]
6. Thiourea Modified Doxorubicin: A Perspective pH-Sensitive Prodrug.
Krasnovskaya OO; Malinnikov VM; Dashkova NS; Gerasimov VM; Grishina IV; Kireev II; Lavrushkina SV; Panchenko PA; Zakharko MA; Ignatov PA; Fedorova OA; Jonusauskas G; Skvortsov DA; Kovalev SS; Beloglazkina EK; Zyk NV; Majouga AG
Bioconjug Chem; 2019 Mar; 30(3):741-750. PubMed ID: 30726065
[TBL] [Abstract][Full Text] [Related]
7. Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin.
Abu Ajaj K; Graeser R; Kratz F
Breast Cancer Res Treat; 2012 Jul; 134(1):117-29. PubMed ID: 22228402
[TBL] [Abstract][Full Text] [Related]
8. Acid-responsive PEGylated doxorubicin prodrug nanoparticles for neuropilin-1 receptor-mediated targeted drug delivery.
Song H; Zhang J; Wang W; Huang P; Zhang Y; Liu J; Li C; Kong D
Colloids Surf B Biointerfaces; 2015 Dec; 136():365-74. PubMed ID: 26433349
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of combination therapy schedules of doxorubicin and an acid-sensitive albumin-binding prodrug of doxorubicin in the MIA PaCa-2 pancreatic xenograft model.
Kratz F; Azab S; Zeisig R; Fichtner I; Warnecke A
Int J Pharm; 2013 Jan; 441(1-2):499-506. PubMed ID: 23149257
[TBL] [Abstract][Full Text] [Related]
10. Drug Delivery Nanoparticles with Locally Tunable Toxicity Made Entirely from a Light-Activatable Prodrug of Doxorubicin.
Schutt C; Ibsen S; Zahavy E; Aryal S; Kuo S; Esener S; Berns M; Esener S
Pharm Res; 2017 Oct; 34(10):2025-2035. PubMed ID: 28791550
[TBL] [Abstract][Full Text] [Related]
11. A pH-sensitive prodrug strategy to co-deliver DOX and TOS in TPGS nanomicelles for tumor therapy.
Xiong S; Wang Z; Liu J; Deng X; Xiong R; Cao X; Xie Z; Lei X; Chen Y; Tang G
Colloids Surf B Biointerfaces; 2019 Jan; 173():346-355. PubMed ID: 30316081
[TBL] [Abstract][Full Text] [Related]
12. Boronic acid/boronate prodrugs for cancer treatment: current status and perspectives.
Maslah H; Pethe S; Labruère R
Future Med Chem; 2021 May; 13(10):859-861. PubMed ID: 33845596
[No Abstract] [Full Text] [Related]
13. Modified peroxamide-based reactive oxygen species (ROS)-responsive doxorubicin prodrugs.
Jafari M; Sriram V; Premnauth G; Merino E; Lee JY
Bioorg Chem; 2022 Oct; 127():105990. PubMed ID: 35785552
[TBL] [Abstract][Full Text] [Related]
14. Self-assembling doxorubicin-tocopherol succinate prodrug as a new drug delivery system: synthesis, characterization, and in vitro and in vivo anticancer activity.
Duhem N; Danhier F; Pourcelle V; Schumers JM; Bertrand O; Leduff CS; Hoeppener S; Schubert US; Gohy JF; Marchand-Brynaert J; Préat V
Bioconjug Chem; 2014 Jan; 25(1):72-81. PubMed ID: 24328289
[TBL] [Abstract][Full Text] [Related]
15. Protease-Responsive Prodrug with Aggregation-Induced Emission Probe for Controlled Drug Delivery and Drug Release Tracking in Living Cells.
Cheng Y; Huang F; Min X; Gao P; Zhang T; Li X; Liu B; Hong Y; Lou X; Xia F
Anal Chem; 2016 Sep; 88(17):8913-9. PubMed ID: 27503607
[TBL] [Abstract][Full Text] [Related]
16. Stimuli-responsive PEGylated prodrugs for targeted doxorubicin delivery.
Xu M; Qian J; Liu X; Liu T; Wang H
Mater Sci Eng C Mater Biol Appl; 2015 May; 50():341-7. PubMed ID: 25746279
[TBL] [Abstract][Full Text] [Related]
17. Acid-activatable prodrug nanogels for efficient intracellular doxorubicin release.
Zhan F; Chen W; Wang Z; Lu W; Cheng R; Deng C; Meng F; Liu H; Zhong Z
Biomacromolecules; 2011 Oct; 12(10):3612-20. PubMed ID: 21905663
[TBL] [Abstract][Full Text] [Related]
18. Self-Targeted Polysaccharide Prodrug Suppresses Orthotopic Hepatoma.
Li D; Xu W; Li P; Ding J; Cheng Z; Chen L; Yan L; Chen X
Mol Pharm; 2016 Dec; 13(12):4231-4235. PubMed ID: 27784155
[TBL] [Abstract][Full Text] [Related]
19. Preparation of a camptothecin prodrug with glutathione-responsive disulfide linker for anticancer drug delivery.
Xu Z; Wang D; Xu S; Liu X; Zhang X; Zhang H
Chem Asian J; 2014 Jan; 9(1):199-205. PubMed ID: 24136878
[TBL] [Abstract][Full Text] [Related]
20. Combretastatin A4 Nanodrug-Induced MMP9 Amplification Boosts Tumor-Selective Release of Doxorubicin Prodrug.
Jiang J; Shen N; Ci T; Tang Z; Gu Z; Li G; Chen X
Adv Mater; 2019 Nov; 31(44):e1904278. PubMed ID: 31549774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
